NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 4天前
Earnings-related names dominate premarket losers
Seeking Alpha - Article · 6天前
Earnings movers dominate premarket losers list
Seeking Alpha - Article · 6天前
NovaBay EPS misses by $0.09, beats on revenue
NovaBay (NYSEMKT:NBY): Q2 GAAP EPS of -$0.15 misses by $0.09. Revenue of $3.98M (+122.3% Y/Y) beats by $0.98M. Shares -3.7%. Press Release
seekingalpha · 08/07 01:25
NovaBay Pharmaceuticals Reports Second Quarter 2020 Financial Results
Business Wire · 08/06 21:05
NovaBay Pharmaceuticals to Hold Second Quarter 2020 Conference Call on August 6
Business Wire · 07/27 11:50
OPK, NBEV, DVAX and ACAD among midday movers
Seeking Alpha - Article · 07/21 16:39
55 Biggest Movers From Yesterday
Gainers Perceptron, Inc. (NASDAQ: PRCP) shares jumped 107% to close at $6.50 on Tuesday after the company received an order from an automotive supplier for its in-line measurement technology.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.